DCOY Decoy Therapeutics Inc.

Price (delayed)

$6.71

Market cap

$3.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$63.98

Enterprise value

-$4.25M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 0

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial ...

Highlights
The debt has plunged by 100% YoY
The EPS has soared by 50% from the previous quarter
The quick ratio has surged by 118% year-on-year but it has declined by 17% since the previous quarter
DCOY's net income has dropped by 134% year-on-year and by 4.1% since the previous quarter
DCOY's equity is down by 34% QoQ

Key stats

What are the main financial stats of DCOY

DCOY stock price

How has the Decoy Therapeutics stock price performed over time
Intraday
-15.81%
1 week
-15.17%
1 month
13.83%
1 year
-95.22%
YTD
-13.86%
QTD
2.75%

Financial performance

How have Decoy Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.18M
Net income
-$13.03M
Gross margin
N/A
Net margin
N/A
DCOY's net income has dropped by 134% year-on-year and by 4.1% since the previous quarter
The operating income has shrunk by 132% YoY and by 4.5% QoQ

Price vs fundamentals

How does DCOY's price correlate with its fundamentals

Growth

What is Decoy Therapeutics's growth rate over time

Valuation

What is Decoy Therapeutics stock price valuation
P/E
N/A
P/B
0.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 50% from the previous quarter
The P/B is 39% lower than the 5-year quarterly average of 1.8
DCOY's equity is down by 34% QoQ

Efficiency

How efficient is Decoy Therapeutics business performance
DCOY's ROE is up by 26% from the previous quarter but it is down by 22% YoY
The ROA is up by 19% QoQ but it is down by 11% YoY

Dividends

What is DCOY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DCOY.

Financial health

How did Decoy Therapeutics financials performed over time
Decoy Therapeutics's total assets is 85% higher than its total liabilities
The quick ratio has surged by 118% year-on-year but it has declined by 17% since the previous quarter
The company's total liabilities has surged by 100% YoY but it fell by 12% QoQ
The debt is 100% less than the equity
The debt has plunged by 100% YoY
DCOY's debt to equity has plunged by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.